November 12, 2010 – A noninvasive imaging technique may help effectively diagnose prostate cancer at an early stage without ionizing radiation. According to a report at the Advances in Contrast Ultrasound – ICUS Bubble Conference, contrast-enhanced ultrasound (CEUS) could help diagnose the most common cancer afflicting American men. "CEUS represents an important opportunity for early detection and for guiding local therapy," said Massimo Mischi of Eindhoven University of Technology in the Netherlands. His work was funded by the Dutch government. Men with elevated levels of prostate specific antigen (PSA) are considered at risk of having prostate cancer, and are typically referred for diagnostic biopsies. But PSA levels may be elevated in many men who do not have prostate cancer and most biopsies are unnecessary, Mischi said. "We know that as many as 76 percent of biopsies were in retrospect unnecessary," he said. "Effective diagnostic imaging is essential because localized therapies can be effective." In CEUS imaging, patients are injected with a special contrast agent that does not contain dye and does not require ionizing radiation. It is approved by the U.S. Food and Drug Administration (FDA) for certain types of cardiac imaging and is approved in Europe, Canada, Asia and South America for pinpointing disease and tumors in other parts of the body. "CEUS can offer a safe and cost effective means of improving the accuracy of ultrasound diagnoses," said Steven Feinstein, M.D., director of echocardiography at Rush University Medical Center in Chicago, director of the conference and co-president of the International Contrast Ultrasound Society. For more information: www.icus-society.org
If you enjoy this content, please share it with a colleague
Related Content
March 27, 2024 — Siemens Healthineers announces the Food and Drug Administration (FDA) clearance of the MAGNETOM Terra.X ...
March 21, 2024 — The Advanced Research Projects Agency for Health (ARPA-H) has appointed American College of Radiology ...
March 21, 2024 — Siemens Healthineers has announced the Food and Drug Administration (FDA) clearance of the CIARTIC Move ...
March 21, 2024 — Artificial intelligence can spot COVID-19 in lung ultrasound images much like facial recognition ...
March 20, 2024 — IceCure Medical Ltd., developer of the ProSense System, a minimally-invasive cryoablation technology ...
The global ultrasound devices market size was estimated at $9.79 billion in 2023 and is anticipated to expand at a ...
March 19, 2024 — Radiology Advances, the first exclusively open-access journal of the Radiological Society of North ...
Have you read the March/April 2024 issue of Imaging Technology News? If not, take some time out of your busy schedule to ...
March 18, 2024 — RamSoft, a global leader in novel cloud-based RIS/PACS radiology solutions for imaging centers and ...
March 15, 2024 — Today, the U.S. Food and Drug Administration (FDA) released its “Artificial Intelligence and Medical ...